Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

Status unconfirmed

Conditions studied: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS

In brief

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Key facts

Study ID

NCT03551002

Run by

University of California, San Diego

People needed

450

Starts

2018-01-01

Expected to finish

2021-12-31

Last updated by the study team

2021-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic
• With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody

You may not qualify if…

• With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020

Where it is running

• Owen Clinic-University of California, San Diego — San Diego, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.